Rob Beathard serves in a critical role supporting corporate and clinical development activities for jCyte. He works closely with the executive management team on cultivating strategic partnerships, securing corporate financing, and allocating resources to meet the Company’s strategic and financial goals. He is also integrally involved with clinical data analysis and trial design optimization.Beathard played a vital role in securing the Ex-US Licensing and Commercialization Agreement for jCell therapy with Santen Pharmaceutical in 2020, with a total deal size over $250 million in addition to tiered, double-digit royalties on net commercial sales in Santen’s licensed regions. Since the agreement was executed, he has served on the Joint Steering Committee between the two companies. Prior to the licensing deal, Beathard was pivotal in securing over $10 million in funding to jCyte in 2019 via the combination of an early-stage equity financing round and a non-dilutive CLIN2 grant award from the California Institute for Regenerative Medicine (CIRM).jCyte hired Beathard as its first fulltime employee in 2017 following the Company’s announcement of its first CLIN2 grant award from CIRM to fund its Phase 2b trial. At that time, he was chiefly responsible for designing and implementing the entire corporate internal control framework and oversaw all finance, accounting, and grant management functions. Prior to joining jCyte, he spent years working for PricewaterhouseCoopers within their assurance and advisory lines of service, with a focus on the life sciences industry. He holds an active certified public accountant license in the state of California.